Browse News
Filter News
Found 3 articles
-
Ionis reports second quarter financial results and recent business achievements
8/9/2022
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the second quarter of 2022 and recent business achievements.
-
GSK and Ionis released promising trial data showing their investigational antisense oligonucleotide, bepirovirsen, could significantly reduce HBsAg and viral DNA levels in patients with CHB.
-
Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
6/25/2022
Ionis Pharmaceuticals, Inc., announced that GSK presented positive results from an interim analysis of the Phase 2b B-Clear clinical study of bepirovirsen, an investigational antisense medicine for the treatment of patients with chronic hepatitis B virus.